financetom
Business
financetom
/
Business
/
KKR Divests Seiyu Stake To Trial Holdings In $2.5 Billion Deal
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
KKR Divests Seiyu Stake To Trial Holdings In $2.5 Billion Deal
Mar 5, 2025 6:59 AM

KKR & Co. Inc. ( KKR ) shares are trading higher premarket on Wednesday. The company disclosed definitive agreements to sell the Japanese supermarket chain Seiyu to Trial Holdings, Inc. for 380 billion yen ($2.5 billion).

This transaction marks a significant milestone for KKR and reflects the substantial efforts made to position Seiyu for ongoing success.

In 2021, KKR acquired a 65% majority stake in Seiyu from Walmart. It later increased its ownership by acquiring an additional 20% stake from Rakuten in 2023. This brought KKR’s total shareholding to 85%.

As part of the current transaction, Walmart will also divest its 15% stake in Seiyu to Trial.

KKR made its investments in Seiyu through its Asian Fund IV.

The transaction is anticipated to close in the second quarter of 2025, pending regulatory approval and customary closing conditions.

Seiyu CEO Tsuneo Okubo said the company has “leveled up” its merchandising strategies and in-store operational capabilities while reinvesting in stores, employees, and IT capabilities.

Also, Darwinbox inked definitive deals for a $140 million investment. Partners Group, representing its clients, and KKR, a leading global investment firm, will co-lead the funding, with additional participation from Gravity Holdings.

KKR has priced its offering of $2.25 billion (45 million shares) in 6.25% Series D Mandatory Convertible Preferred Stock at $50.00 per share, up from the originally planned $1.50 billion (30 million shares).

The underwriters have a 30-day option to purchase an additional $337.5 million (6.75 million shares) to cover any over-allotments.

The offering is expected to close on March 7, 2025, subject to customary conditions.

KKR also entered into definitive agreements with CVC to become the largest shareholder in Healthcare Global Enterprises (HCG) and take full operational control for $400 million.

Investors can gain exposure to the stock via FM Focus Equity ETF ( FMCX ) and EA Series Trust WHITEWOLF Publicly Listed Private Equity ETF .

Price Action: KKR shares are up 0.76% at $121.65 premarket at the last check Wednesday.

Read Next:

KKR Boosts Enilive Ownership To 30% With ~$614 Million Investment: Details

Image: Shutterstock

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Papa John's Valuation 'Overly Pessimistic' Assessment of Long-Term Growth Potential, Earnings Power, Wedbush Says
Papa John's Valuation 'Overly Pessimistic' Assessment of Long-Term Growth Potential, Earnings Power, Wedbush Says
Aug 9, 2024
11:17 AM EDT, 08/09/2024 (MT Newswires) -- Papa John's International's (PZZA) current valuation reflects an overly pessimistic assessment of its long-term growth potential and underlying earnings power even as the pizza chain faces short-term same-store sales fluctuations, Wedbush said in a note emailed Thursday. Papa John's Q2 earnings exceeded expectations due to better-than-expected performance in company-owned stores and operating margin....
Algonquin Shares Plunge: Posts Mixed Q2, Sells Renewables Energy Business & Cuts Dividend
Algonquin Shares Plunge: Posts Mixed Q2, Sells Renewables Energy Business & Cuts Dividend
Aug 9, 2024
Algonquin Power & Utilities Corp. ( AQNB ) shares are trading lower today after it reported second-quarter FY24 results and disclosed the sale of its renewable energy business.  Q2 Earnings: The company reported revenue of $598.60 million (-5% Y/Y), missing the consensus of $625.00 million. Adjusted EPS of $0.09 exceeded the street view of $0.08. Adjusted Funds from Operations rose 12% Y/Y to $167.9...
Skin Cancer-Focused Iovance Biotherapeutics Reports Better-Than-Expected 2024, 2025 Outlook, Stock Surges
Skin Cancer-Focused Iovance Biotherapeutics Reports Better-Than-Expected 2024, 2025 Outlook, Stock Surges
Aug 9, 2024
Iovance Biotherapeutics Inc ( IOVA ) stock is trading higher on Friday after the company issued upbeat guidance for 2024 and 2025 and better-than-expected second-quarter earnings. On Thursday, the cancer cell therapy maker Iovance reported second-quarter sales of $31.12 million, surpassing the consensus of $24.6 million. The company reported EPS loss of $(0.34), down from $(0.47) a year ago, beating...
--Cisco Systems to Eliminate Thousands of Jobs in Second Workforce Reduction This Year, Reuters Says
--Cisco Systems to Eliminate Thousands of Jobs in Second Workforce Reduction This Year, Reuters Says
Aug 9, 2024
11:16 AM EDT, 08/09/2024 (MT Newswires) -- Price: 45.56, Change: -0.27, Percent Change: -0.59 ...
Copyright 2023-2026 - www.financetom.com All Rights Reserved